# VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients

> **NCT02113033** · PHASE2 · COMPLETED · sponsor: **LivaNova** · enrollment: 15 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DEVICE:** Equilia® Vagal Nerve Stimulation

## Key facts

- **NCT ID:** NCT02113033
- **Lead sponsor:** LivaNova
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-07
- **Primary completion:** 2016-02-22
- **Final completion:** 2016-09-20
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113033, "VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02113033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*